Home / Resources (page 110)



International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #101: Pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD) Part 3

Cause of NAFLD: physical inactivity: Although physical training predominantly enhances muscle insulin sensitivity, cross-sectional epidemiologic data and studies on effects of physical training suggest that exercise may decrease liver fat even in the face of unchanged body weight [50]. In a cross-sectional study in 72,359 healthy Korean adults, subjects who were exercising regularly had a 28–53% lower risk of NAFLD across almost all BMI deciles.

Read More »

CGM Future

Do you believe that glucose monitors will be a thing of the past as continuous glucose monitors (CGM) become less expensive and more accurate? Follow the link to see how you and your colleagues compare!

Read More »

A1C Treatment Plan

A 54-year-old male presents to your office for an initial visit. His past medical history is significant for hypertension, hypertriglyceridemia and acute pancreatitis. His current lab results show an A1C 9.1%, which is confirmed on a repeat lab. You would like to start him on an antihyperglycemic treatment regimen. Which of the following two-drug combinations is contraindicated for this patient? A. Metformin + a sulfonylurea B. Metformin + an insulin C. Metformin + a meglitinide D. Metformin + a GLP-1 receptor agonist Follow the link to get the answer.

Read More »

The Next CGMS is the Senseonics Eversence System

Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

Read More »

Julia Greenstein Current Interview

Julia Greenstein, Ph. D. is the JDRF Vice President of Discovery Research, which includes early-stage programs across the JDRF portfolio. Dr. Greenstein has more than 20 years of experience in the corporate biotechnology arena, holding leadership positions that have helped accelerate discoveries to market.

Read More »